Pro Medicus Ltd (ASX: PME) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $12.14 billion
P/E Ratio 57.97
Dividend Yield 0.48%
Shares Outstanding 104.47 million
Earnings per share 2.243
Dividend per share 0.64
Year To Date Return -42.98%
Earnings Yield 1.73%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Pro Medicus Ltd (ASX: PME)
Latest News

Two happy scientists analysing test results.
Healthcare Shares

2 ASX 200 healthcare shares just upgraded by Citi analysts

Experts think that these ASX shares could offer healthy returns.

Read more »

A cute young girl wears a straw hat and has a backpack strapped on her back as she holds a globe in her hand with a cheeky smile on her face.
Opinions

2 ASX shares to buy with exciting global growth potential: fund manager

These two ASX shares are expanding globally, giving them big growth runways.

Read more »

Group of shocked people gather around screen
Share Market News

ASX 200 in freefall as CBA's prediction of a soft landing might have just been torpedoed by huge interest rate call

Big four banks plunge as fears profit margins have peaked.

Read more »

Three businesspeople leap high with the CBD in the background.
Earnings Results

3 ASX 200 shares on the move amid strong earnings updates

All three of these companies generated bigger profits.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Opinions

ASX shares: Is this my once-in-a-lifetime chance for mega returns?

Should investors be jumping on the opportunities that we’re seeing?

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
52-Week Highs

Happy days! 8 ASX 200 shares smashing new 52-week highs on Thursday

These ASX 200 shares are scaling new heights during Thursday's session...

Read more »

Group of medical professionals high five
52-Week Highs

5 ASX 200 shares smashing new 52-week highs on Wednesday

Some of the market's most iconic stocks are peaking at long-forgotten heights today.

Read more »

A piggy bank blasts off into the sky.
52-Week Highs

4 ASX 200 shares hitting new 52-week highs on Monday

These ASX giants are defying the market's downturn to post long-forgotten highs.

Read more »

ASX fund manager Ray David
Ask a Fund Manager

Two ASX sectors to buy right now (and two to avoid like the plague): fundie

Ask A Fund Manager: Schroders' Ray David explains which stocks still look too expensive and which ones are excellent value…

Read more »

Five people are leaping in the shallows of the beach water as sunset shines gold on them.
52-Week Highs

5 ASX 200 shares rocketing to new 52-week highs on Tuesday

These stocks are making the most of the ASX 200's strong start to 2023.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

This ASX 200 healthcare share just hit a new 52-week high. Here's why

The ASX 200 health imaging company is edging back towards its all-time highs.

Read more »

A man in a suit looks surprised as he looks through binoculars.
Growth Shares

2 ASX 200 growth shares to watch for a boom 2023: expert

This pair of tech stocks has defied the odds to put a smile on investors' faces last year. One fundie…

Read more »

Frequently Asked Questions

Yes, the company historically pays two fully franked dividends a year. 

Pro Medicus generally pays its shareholder dividends in March and October.

Pro Medicus Ltd listed on the ASX on 10 October 2000.

PME ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Pro Medicus Ltd

Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
26 Feb 2026 Anthony Hall Buy 8,146 $993,812
On-market trade.
25 Feb 2026 Anthony Hall Buy 9,000 $1,029,690
On-market trade.
24 Feb 2026 Sam Hupert Buy 4,500 $489,240
On-market trade.
24 Feb 2026 Anthony Hall Buy 8,500 $936,105
On-market trade.
23 Feb 2026 Peter Kempen Buy 400 $46,572
On-market trade.
13 Feb 2026 Deena Shiff Buy 788 $99,815
On-market trade.
13 Feb 2026 Anthony Glenning Buy 2,080 $249,204
On-market trade.
29 Dec 2025 Peter Kempen Buy 600 $134,400
On-market trade. As per announcement - 30/12/2025
23 Dec 2025 Sam Hupert Buy 2,250 $499,477
On-market trade.
23 Dec 2025 Anthony Hall Buy 2,270 $500,103
On-market trade.
22 Dec 2025 Sam Hupert Buy 2,250 $498,262
On-market trade.
22 Dec 2025 Anthony Hall Buy 2,250 $499,275
On-market trade.
03 Sep 2025 Sam Hupert Transfer 50,000 $14,950,000
Off-market transfer. Estimated value
12 Mar 2025 Anthony Glenning Buy 50 $10,979
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
Mr Hupert, left general practice in late 1984 to devote himself full time to managing the Group. Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
Mr Hall has been principal architect and developer of the core software systems that underpin Visage RIS.
Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Boards of St Hilda's College Ltd, University of Melbourne, and the Olivia Newton-John Cancer Research Institute. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honors. He became Chairman in August 2010 before which he served as a Non-Executive Director of the Company.
Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
Ms Williams is also a non-executive director of Vocus Group, Swimming Australia, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit & Risk Committee of ASC and Vocus Group and is a member of the Audit & Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Djerriwarrh Investments, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Nonexecutive member of the Foreign Investment Review Board. Alice is Chair of the Risk committee and serves on the People & Culture committee.
Ms Deena Robyn Shiff Non-Executive Director Aug 2020
Ms Shiff is an Independent Board Member of the Global Alliance for Vaccines and Immunization, the multi-lateral global health fund based in Geneva, the Chairman of AROSE (Australian Remote Operations in Space and Earth), and since July 2025, the Chairman of the Australian Telecommunications Alliance. and Chairman of the Care Economy Co Operative Research Centre. She also chairs the International Advisory Board of the Australian Research Centre of Excellence on Automated Decision Making and Society. Deena is Chair of the People & Culture committee and serves on the Risk committee.
Mr Anthony James Glenning Non-Executive Director May 2016
Mr Glenning is a fund adviser to Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. Anthony has previously been an Investment Director at Starfish Ventures and was the founder and CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He has also held senior software engineering positions at Google and Sun Microsystems Inc. Anthony also serves on the People & Culture committee and Risk committee.
Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
Dr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialization Committee, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins and a member of the Investment Committee for the CUREAtor Plus.Dementia and Cognitive Decline Grants which is funded by the Australian Medical Research Future Fund. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.
Ms Danny English Company Secretary Mar 2023
-
Clayton Hatch Chief Financial Officer
-
Danny English Company Secretary
-
Malte Westerhoff General Manager Europe and Global Chief Technology Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr A Hall (multiple shareholdings) 24,144,000 23.11%
Dr S Hupert (multiple shareholdings) 24,137,660 23.11%
HSBC Custody Nominees (Australia) Limited 23,739,921 22.73%
J P Morgan Nominees Australia Limited 7,952,739 7.61%
Citicorp Nominees Pty Ltd 7,726,022 7.40%
BNP Paribas Noms Pty Ltd 1,781,046 1.70%
Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen multiple shareholdings) 629,082 0.60%
Mr Michael Wu 439,242 0.42%
Grain Exporters (Australia) Pty Ltd 437,925 0.42%
National Nominees Limited 402,482 0.39%
Netwealth Investments Limited 297,897 0.29%
Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi 281,417 0.27%
Mr Colin Gregory Organ 271,000 0.26%
Mr John Charles Plummer 250,000 0.24%
Mr Danny Tauber 164,007 0.16%
Mr Bram Vander Jagt & Mrs Maaike Vander Jagt 140,000 0.13%
Mr Sean Michael Lambright 127,587 0.12%
A Haig Retirement Manager Pty Ltd 114,723 0.11%
Mr Kenneth John Vander Jagt & Mrs Tanya Vander Jagt 103,000 0.10%
BNP Paribas Noms (Nz) Ltd 90,680 0.09%

Profile

since

Note